144 related articles for article (PubMed ID: 11064444)
1. Quality of life during the first 6 months of interferon-beta treatment in patients with MS.
Arnoldus JH; Killestein J; Pfennings LE; Jelles B; Uitdehaag BM; Polman CH
Mult Scler; 2000 Oct; 6(5):338-42. PubMed ID: 11064444
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life in patients with relapsing-remitting multiple sclerosis treated with subcutaneous interferon β-1a in Iran.
Pakdaman H; Amini Harandi A; Gharagozli K; Abbasi M; Tabassi A; Ashrafi F; Ghaffarpor M; Sharifi S; Delavar Kasmae H; Assarzadegan F; Arabahmadi M; Behnam B
Int J Neurosci; 2017 Jun; 127(6):501-507. PubMed ID: 27279451
[TBL] [Abstract][Full Text] [Related]
3. Quality of life in multiple sclerosis: influence of interferon-beta1 a (Avonex) treatment.
Vermersch P; de Seze J; Delisse B; Lemaire S; Stojkovic T
Mult Scler; 2002 Oct; 8(5):377-81. PubMed ID: 12356203
[TBL] [Abstract][Full Text] [Related]
4. Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up.
Flechter S; Vardi J; Pollak L; Rabey JM
J Neurol Sci; 2002 May; 197(1-2):51-5. PubMed ID: 11997066
[TBL] [Abstract][Full Text] [Related]
5. Improvement of health-related quality of life in relapsing remitting multiple sclerosis patients after 2 years of treatment with intramuscular interferon-beta-1a.
Jongen PJ; Sindic C; Carton H; Zwanikken C; Lemmens W; Borm G;
J Neurol; 2010 Apr; 257(4):584-9. PubMed ID: 19921303
[TBL] [Abstract][Full Text] [Related]
6. Quality of life in 1000 patients with early relapsing-remitting multiple sclerosis.
Putzki N; Fischer J; Gottwald K; Reifschneider G; Ries S; Siever A; Hoffmann F; Käfferlein W; Kausch U; Liedtke M; Kirchmeier J; Gmünd S; Richter A; Schicklmaier P; Niemczyk G; Wernsdörfer C; Hartung HP;
Eur J Neurol; 2009 Jun; 16(6):713-20. PubMed ID: 19475754
[TBL] [Abstract][Full Text] [Related]
7. Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy.
Trojano M; Liguori M; Paolicelli D; Zimatore GB; De Robertis F; Avolio C; Giuliani F; Fuiani A; Livrea P;
Mult Scler; 2003 Oct; 9(5):451-7. PubMed ID: 14582768
[TBL] [Abstract][Full Text] [Related]
8. Change in quality of life in patients with relapsing-remitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon {beta}-1a.
Miller DM; Weinstock-Guttman B; Bourdette D; You X; Foulds P; Rudick RA
Mult Scler; 2011 Jun; 17(6):734-42. PubMed ID: 21300736
[TBL] [Abstract][Full Text] [Related]
9. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.
Meca-Lallana JE; de Mingo-Casado P; Amorin-Díaz M; Martínez-Navarro ML; Barreiro AF
Clin Ther; 2010 Jun; 32(6):1061-6. PubMed ID: 20637960
[TBL] [Abstract][Full Text] [Related]
10. Interferon-beta-1a treatment has a positive effect on quality of life of relapsing-remitting multiple sclerosis: results from a longitudinal study.
Patti F; Pappalardo A; Montanari E; Pesci I; Barletta V; Pozzilli C
J Neurol Sci; 2014 Feb; 337(1-2):180-5. PubMed ID: 24433926
[TBL] [Abstract][Full Text] [Related]
11. Time of interferon-beta 1a injection and duration of treatment affect clinical side effects and acute changes of plasma hormone and cytokine levels in multiple sclerosis patients.
Kümpfel T; Schwan M; Pollmächer T; Yassouridis A; Uhr M; Trenkwalder C; Weber F
Mult Scler; 2007 Nov; 13(9):1138-45. PubMed ID: 17967841
[TBL] [Abstract][Full Text] [Related]
12. Depression in multiple sclerosis associated with interferon beta-1a (Rebif).
Pandya R; Patten S
Can J Psychiatry; 2002 Sep; 47(7):686. PubMed ID: 12355685
[No Abstract] [Full Text] [Related]
13. [Quality of life in patients with remitting-relapsing multiple sclerosis in Germany].
Haupts M; Elias G; Hardt C; Langenbahn H; Obert H; Pöhlau D; Sczesni B; von Wussow P
Nervenarzt; 2003 Feb; 74(2):144-50. PubMed ID: 12596015
[TBL] [Abstract][Full Text] [Related]
14. Interferon-beta treatment for patients with multiple sclerosis: the patients' perceptions of the side-effects.
Gottberg K; Gardulf A; Fredrikson S
Mult Scler; 2000 Oct; 6(5):349-54. PubMed ID: 11064446
[TBL] [Abstract][Full Text] [Related]
15. A randomized open label study of pain medications (naproxen, acetaminophen and ibuprofen) for controlling side effects during initiation of IFN beta-1a therapy and during its ongoing use for relapsing-remitting multiple sclerosis.
Leuschen MP; Filipi M; Healey K
Mult Scler; 2004 Dec; 10(6):636-42. PubMed ID: 15584488
[TBL] [Abstract][Full Text] [Related]
16. Disease-specific quality of life in multiple sclerosis: the effect of disease modifying treatment.
Lily O; McFadden E; Hensor E; Johnson M; Ford H
Mult Scler; 2006 Dec; 12(6):808-13. PubMed ID: 17263011
[TBL] [Abstract][Full Text] [Related]
17. Factors that predict health-related quality of life in patients with relapsing-remitting multiple sclerosis.
Miller DM; Rudick RA; Baier M; Cutter G; Doughtery DS; Weinstock-Guttman B; Mass MK; Fisher E; Simonian N
Mult Scler; 2003 Feb; 9(1):1-5. PubMed ID: 12617260
[TBL] [Abstract][Full Text] [Related]
18. Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study.
Bermel RA; Weinstock-Guttman B; Bourdette D; Foulds P; You X; Rudick RA
Mult Scler; 2010 May; 16(5):588-96. PubMed ID: 20167591
[TBL] [Abstract][Full Text] [Related]
19. [Interferons beta in patients with multiple sclerosis].
Vlasov IaV; Kuznetsova NI; Poverennova IE; Khivintseva EV
Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(7):54-5. PubMed ID: 16117149
[No Abstract] [Full Text] [Related]
20. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis.
Arroyo González R; Kita M; Crayton H; Havrdova E; Margolin DH; Lake SL; Giovannoni G;
Mult Scler; 2017 Sep; 23(10):1367-1376. PubMed ID: 27885061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]